The commencement of phase-II/III study of BBV87 in Costa Rica is a milestone and a first step towards developing a promising vaccine candidate against Chikungunya, an exhausting disease.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/3jf0Ngt
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» IVI and Bharat Biotech jointly launch Global Chikungunya Vaccine phase-II/III trial in Costa Rica
https://ift.tt/eA8V8J
No comments:
Post a Comment